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INTRODUCTION 
Substantial efforts have recently been focused upon 
placing a drug or drug delivery system in a particular 
region of the body for extended period of time1. From a 
technological point of view, an ideal Sustained Release 
Mucoadhesive (SRM) dosage form must have three 
properties. It must maintain its position in the mouth for a 
few hours, release the drug in a controlled fashion and 
provide the drug release in a unidirectional way towards 
the mucosa1. Microspheres form an important part of such 
novel drug delivery systems. However, the success of these 
microspheres is limited owing to their short residence time 
at the site of absorption. It would, therefore, be 
advantageous to have means for providing an intimate 
contact of the drug delivery system with the absorbing 
membranes. This can be achieved by coupling bioadhesion 
characteristics to microspheres and developing bioadhesive 
microspheres.2-7 Bioadhesive microspheres have 
advantages such as efficient absorption and enhanced 
bioavailability of drugs owing to a high surface-to-volume 
ratio, a much more intimate contact with the mucus layer, 
and specific targeting of drugs to the absorption site.8, 9 
Mucoadhesive microspheres that are retained in the 
stomach would increase the drug absorption and decrease 
dosing frequency which provides better patient compliance 
as compared to conventional dosage forms.  
Repaglinide is an oral hypoglycaemic agent which acts by 
stimulating the release of insulin from pancreatic beta-cells 
by inhibition of potassium efflux resulting in closure of 
ATP regulates K+ channels10. 
The bioavailability of the oral formulation was found to be 
63%11. The effective control of diabetes type-II requires  
 
 
administration of Repaglinide 0.5 – 4 mg three times daily. 
Owing to its short biological half life (1 hours) and low 
bioavailability (63%)12;  it’s necessary to develop  a 
sustained release mucoadhesive dosage form of 
Repaglinide which adhere to the mucosa and release the 
drug in sustained release manner.  
These microspheres would prolonged, relatively constant 
effective level of Repaglinide and improve patient 
compliance.  Thus SRM microspheres of Repaglinide are 
suitable candidate for effective control of diabetes type-II. 
Literature survey revealed that Carbopol (CP) 13-15 and 
hydroxy propyl methyl cellulose (HPMC) 16, 17 are the 
polymer which shows good mucoadhesive properties, high 
drug entrapment efficiency and release the drug in 
sustained release manner. Therefore in the present study 
Repaglinide is selected as a model drug and CP and HPMC 
are chosen as a mucoadhesive polymer for design and 
evaluation SRM Microspheres for treatment of diabetes 
type-II.  
MATERIALS: 
Repaglinide was obtained as gift sample from Sun 
Pharmaceuticals Ltd., Mumbai, INDIA. CP was gifted 
from Colorcon Asia Pvt. Ltd, Goa INDIA. HPMC was 
received as gift sample from Zydus-Cadila Healthcare Ltd, 
Ahmadabad, INDIA. n-Hexane and span 20 were procured 
from central drug house, New Delhi INDIA. Liquid 
paraffin was procured from Loba Chemie Pvt. Ltd., 
Mumbai INDIA. All the reagents were used of analytical 
grade.   
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METHODS:   
Assay of Repaglinide: 
Repaglinide was estimate using an UV spectrophotometer 
method. Different solutions of Repaglinide were prepared 
in simulated gastric fluid (pH 1.2) and absorbance was 
measured on Shimazdu UV spectrophotometer at 247 nm. 
The method was validated for linearity, accuracy, and 
precision. The regression coefficient was found to be 
0.991. 
Preparation of microspheres7, 18: 
Mucoadhesive microspheres of Repaglinide were prepared 
by emulsification solvent evaporation method using 
various ratios of CP and HPMC. For this, aqueous solution 
of drug and polymer is prepared. Then drug and polymer 
solution was added drop wise to the liquid paraffin 
containing 0.5 % span 20 as an emulsifying agent with 
constant stirring. The constant stirring was carried out 
using magnetic stirrer. The beaker and its content were 
heated at 800C with constant stirring for 4 hrs until the 
aqueous phase was completely removed by evaporation. 
The liquid paraffin was decanted and collected 
microsphere were washed 5 times with n-hexane, filtered 
through whattman’s filter paper and dried in hot air oven at 
50 C for 2 hours. Table 1 shows composition of various 
formulations of microspheres. 
Surface morphology
19, 20
: 
The surface morphology and structure were visualized by 
scanning electron microscopy (SEM). The samples were 
prepared by lightly sprinkling the microspheres powder on 
a double side adhesive tape which already shucked to on 
aluminum stubs. The stubs were then placed into fine coat 
ion sputter for gold coating. After gold coating samples 
were randomly scanned for particle size and surface 
morphology 
 
Table-1 Composition of drug loaded microspheres 
Formulation 
code 
Drug Stirring Speed Variables 
Polymer conc. Phase volume ratio 
(D/C) Carbopol 934 HPMC 
C1:8 10 mg 500 rpm 1.0% - 1:8 
C1:12 10 mg 500 rpm 1.0% - 1:12 
C1:16 10 mg 500 rpm 1.0% - 1:16 
H1:8 10 mg 500 rpm - 1.0% 1:8 
H1:12 10 mg 500 rpm - 1.0% 1:12 
H1:16 10 mg 500 rpm - 1.0% 1:16 
CH1:8 10 mg 500 rpm 1.0% 1.0% 1:8 
CH1:12 10 mg 500 rpm 1.0% 1.0% 1:12 
CH1:16 10 mg 500 rpm 1.0% 1.0% 1:16 
 
Particle Size
21, 22
: 
Particle size analysis of drug-loaded microspheres was 
performed by optical microscopy using a compound 
microscope (Erma, Tokyo, Japan). A small amount of dry 
microspheres was suspended in n-hexane (10 mL). The 
suspension was ultra-sonicated for 5 seconds. A small drop 
of suspension thus obtained was placed on a clean glass 
slide. The slide containing microspheres was mounted on 
the stage of the microscope and 300 particles were 
measured using a calibrated ocular micrometer. The 
average particle size was determined by using the 
Edmondson's equation D mean = ∑nd/∑n, where n= number 
of microspheres observed and d= mean size range. The 
process was repeated 3 times for each batch prepared. 
Drug entrapment efficacy
21
: 
50 mg of microsphere were taken and drug was extracted 
from microspheres by digesting for 24 hours with 10 ml of 
simulated gastric fluid (pH 1.2). During this period the 
suspension was agitated. After 24 hours, the solution was 
filtered and the filtrate was analyzed for the drug content. 
The drug entrapment efficiency was calculated using the 
following formula:  
Entrapment efficiency = (Practical drug 
content/theoretical drug content) ×100 
 
 
In-vitro mucoadhesivity
7, 8, 23
: 
The mucoadhesive properties of the microspheres were 
evaluated by in vitro wash-off test as reported by Lehr et 
al. A 1-cm by 1-cm piece of rat stomach mucosa was tied 
onto a glass slide (3-inch by 1-inch) using thread. 
Microspheres were spread (∽50) onto the wet, rinsed, 
tissue specimen, and the prepared slide was hung onto one 
of the groves of a USP tablet disintegrating test apparatus. 
The disintegrating test apparatus was operated such that the 
tissue specimen was given regular up and down 
movements in a beaker containing the simulated gastric 
fluid (pH 1.2). At hourly intervals up to 10 hours, the 
number of microspheres still adhering onto the tissue was 
counted. Percent mucoadhesion was given by the following 
formula. 
% mucoadhesion = (no. of microspheres remains / no. of 
applied microspheres) ×100 
The observations are expressed in figure 2-4. 
In-vitro drug release
24, 25
: 
In-vitro drug release study was carried out in USP XXI 
paddle type dissolution test apparatus using simulated 
gastric fluid (pH 1.2) as dissolution medium, volume of 
dissolution medium was 900 ml and bath temperature was 
maintained at (37±1) °C throughout the study. Paddle 
speed was adjusted to 50 rpm. An interval of 1 hour, 10 ml 
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of sample was withdrawn with replacement of 10 ml fresh 
medium and analyzed for drug content by UV-Visible 
spectrophotometer at 247 nm. All the experimental units 
were analyzed in triplicate (n=3). Cumulative percentage 
drug release was calculated using an equation obtained 
from a standard curve. The observations are expressed in 
figure 5 to 8 and table 3. 
RESULTS AND DISCUSSION 
Surface morphology: 
Surface morphology of the mucoadhesive microspheres 
was examined by scanning electron microscopy (SEM). 
The SEM showed that the microspheres obtained from all 
the formulations are spherical with smooth surface. The 
SEM showed that CP produced spherical with smooth 
surface microspheres due to their high solubility in water13, 
14. The SEM of microsphere of formulation C1:8 are 
shown in figures 1
 
 
Figure- 1 SEM of formulation C1:8 showing population of microspheres 
Particle size analysis: 
Particle size analysis of different formulations was done by 
optical microscopy20, 21.  The average particle size was 
found to be in the range of 28.43 to 64.78 μm. The mean 
particle size was significantly varied according to type of 
polymer used for the preparation of microspheres; this may 
be due to fact that difference in the viscosity of the 
polymer solution13. Since high viscosity of polymer 
solution requires high shearing energy for breaking of 
droplets of the emulsion. Microspheres containing HPMC 
are larger as compared to CP microspheres because HPMC 
solution has more viscosity at the same concentration. 
Particle size decreased with increase in volume of 
continuous phase due to the fact that increased in 
continuous phase, more efficiently utilized the energy 
produced by stirring, which leads to further decrease in 
droplets size of internal phase. increase in concentration of 
polymer in internal phase leads to increase in size of 
microspheres because at higher concentration polymer 
solution have more viscosity which requires more energy 
to breaking the droplets of dispersed phase. Results of 
particle size analysis are shown in table 2. 
Drug entrapment efficiency: 
Drug content in different formulations was estimated by U 
V Spectrophotometric method. Percent drug loading 
efficiency of microspheres was found in the range of 62.13 
to 76.5 % (table- 2). Formulation CH1:8 containing blend 
of CP and HPMC showed maximum % drug loading about 
76.5 % because these microspheres have larger size as 
compared to other formulations. Whereas formulation 
H1:16 containing HPMC showed minimum % drug 
loading about 63% because these microspheres are small in 
size which results more loss of drug from surface during 
washing of microspheres. Increase in polymer 
concentration of internal phase also increase in drug 
entrapment of microspheres. Rank order of % drug loading 
of various formulations was found to be as follows:   
CH1:8>C1:8>C1:12>CH1:12>C1:16>CH1:16>H1:8>H1:1
2>H1:16 
In-vitro mucoadhesivity test: 
To assess the mucoadhesive property of microspheres, In-
vitro wash-off test was performed for all the formulations. 
In the mucoadhesion process, it is necessary for swelling 
and expansion of the polymer chain since interpenetration 
and entanglement of the polymers and the mucous 
networks are considered to be responsible for adhesion13. 
Therefore, bioadhesives should swell and expand rapidly 
when they come in contact with water. Adhesion of 
polymer with the mucus membrane is mediate by hydration 
in the case of hydrophilic polymer. Upon hydration these 
polymers becomes sticky and adhere to mucus membrane. 
A high percentage of adhesion indicates that microspheres 
have excellent mucoadhesion to mucosal tissue. Carbopols 
are interacts with the mucin, resulting in adhesion of the 
polymer to the mucin. Formulation H1:8 containing HPMC 
showed the highest mucoadhesivity. Formulation C1:16 
containing CP showed the shortest mucoadhesion time due 
to the small size of microsphere which takes short time for 
solubilization. The results of % mucoadhesivity test of all 
the formulations are expressed in figure 2, 4 and 5.  
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Drug release study: 
Drug release form these microspheres were slow, extended 
and dependent on the type of polymer and concentration of 
polymer used. The rate of release of drug from the 
bioadhesive microspheres was slow and found to further 
decrease with increase in drug to polymer ratio. 
Formulation H1:16 containing HPMC showed the fast drug 
release due to rapid swelling property in dissolution 
environment (0.1 N HCl). Dissolution medium permeation 
in to the microspheres is facilitated due to high swelling 
action of the HPMC which leads to more medium for the 
transport of the drug is available. While HPMC 
microspheres showed the least drug release. A drug release 
form microsphere is significantly affected by the size of 
microspheres. Increase in polymer concentration leads to 
increase in size of microspheres thus drug release from 
microspheres having low drug to polymer ratio found to 
significantly decrease. FormulationC1:16 shown fastest 
drug release among all the formulation due to fact that 
these microspheres are small in size. Results of drug 
release study are expressed in figure 6 to 9.  
Table 2: % yield, % drug entrapment and Particle size of microspheres 
Formulatio
n code 
% yield Particle 
size (µm) 
% Drug 
entrapment 
C1:8 78.46±2.45 44.23 75.23 
C1:12 75.65±2.55 35.88 71.31 
C1:16 72.26±2.80 28.43 69.50 
H1:8 73.22±2.40 59.44 66.45 
H1:12 70.83±2.64 48.94 64.86 
H1:16 66.85±1.90 41.25 62.13 
CH1:8 80.50±2.12 64.78 76.50 
CH1:12 76.40±2.35 50.34 70.20 
CH1:16 74.36±2.30 43.68 68.84 
 
 
Figure 2: Comparative % mucoadhesion of formulations C1:8, C1:12 & C1:16 
Design-Expert® Software
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Figure 3: Surface Response Curve shows effect of polymer conc and phase volume ratio on drug entrapment
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Figure 4: Comparative % mucoadhesion of formulations 
C1:8, H1:8 & CH1:8  
 
Figure 5: Comparative % mucoadhesion of formulations 
C1:12, H1:12 & CH1:12
 
 
Figure 6: Cumulative % drug release from formulation 
C1:8, C1:12 & C1:16 
 
 
 
 
 
 
Figure 7: Cumulative % drug release from formulation 
C1:8, H1:8 & CH1:8 
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Figure 8: Cumulative % drug release from formulation 
C1:12, H1:12 & CH1:12 
 
Figure 9: Cumulative % drug release from formulation 
C1:16, H1:16 & CH1:16
Table 3: % Mucoadhesion, t50 and t80 of Repaglinide Release from microspheres 
Formulation % Mucoadhesion 
after 1 Hour 
T50 of drug 
release(Min) 
T80 of drug 
release(Min) 
C1:8 80.25±2.95 280 544 
C1:12 77.62±2.23 263 521 
C1:16 76.60±2.91 254 420 
H1:8 84.65±2.23 238 448 
H1:12 81.62±3.86 235 431 
H1:16 82.82±2.94 223 415 
CH1:8 82.65±2.63 292 498 
CH1:12 81.42±2.86 264 497 
CH1:16 79.82±2.74 298 470 
 
Table 4: Application of kinetic models to access drug release behavior 
 
Formulation  
Code 
Kinetic Models 
Zero Order First Order Second Order 
C 1:8 y = 7.5766x + 8.2311 
R² = 0.964 
y = 37.159ln(x) - 2.5625 
R² = 0.9718 
y = -0.3971x2 + 12.739x - 2.0931 
R² = 0.9979 
C 1:12 y = 7.6829x + 9.6586 
R² = 0.9501 
y = 37.83ln(x) - 1.4454 
R² = 0.976 
y = -0.4753x2 + 13.862x - 2.7 
R² = 0.9966 
C 1:16 y = 7.9215x + 11.553 
R² = 0.9161 
y = 39.522ln(x) - 0.67 
R² = 0.9715 
y = -0.6512x2 + 16.387x - 5.3775 
R² = 0.9953 
H 1:8 y = 7.6754x + 13.309 
R² = 0.9225 
y = 37.664ln(x) + 2.7216 
R² = 0.9752 
y = -0.6119x2 + 15.631x - 2.6018 
R² = 0.9975 
H 1:12 y = 7.6357x + 14.402 
R² = 0.9096 
y = 37.473ln(x) + 3.9524 
R² = 0.9711 
y = -0.6591x2 + 16.204x - 2.7343 
R² = 0.9964 
H 1:16 y = 7.5676x + 15.634 
R² = 0.9072 
y = 36.971ln(x) + 5.6727 
R² = 0.977 
y = -0.6712x2 + 16.294x - 1.8179 
R² = 0.9985 
CH 1:8 y = 8.1384x + 5.2654 
R² = 0.9621 
y = 40.36ln(x) - 7.3768 
R² = 0.9529 
y = -0.4121x2 + 13.495x - 5.4481 
R² = 0.9936 
CH 1:12 y = 8.1681x + 5.5983 
R² = 0.9594 
y = 40.509ln(x) - 7.0688 
R² = 0.9526 
y = -0.4263x2 + 13.71x - 5.4849 
R² = 0.9928 
CH 1:16 y = 8.1675x + 6.6591 
R² = 0.9525 
y = 40.407ln(x) - 5.7532 
R² = 0.9496 
y = -0.4635x2 + 14.193x - 5.3925 
R² = 0.9918 
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FUTURE PROSPECTS:
 
 
While the control of drug release profiles has been a major 
aim of pharmaceutical research and development in the 
past two decades, the control of GI transit profiles could be 
the focus of the next two decades and might result in the 
availability of new products with better therapeutic 
possibilities and substantial benefits for patients. 
Mucoadhesive microspheres would become the promising 
candidate for delivery various drugs in sustained release 
manner. Dosing frequency and loss of drug also reduced 
by use of such type of formulations. Thus SRM 
microspheres of Repaglinide would become a promising 
candidate for therapy of diabetes type-II in the future. 
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